Skip to main content

Dr. Hedy Kindler

Dr. Hedy Kindler

Professor of Medicine, Section of Hematology/Oncology

Dr. Hedy Kindler is a medical oncology at University of Chicago Medicine in Chicago, IL, specializing in the treatment of malignant mesothelioma. Dr. Kindler has published 200+ peer-reviewed papers and is affiliated with University of Chicago Medicine.

Last verified: 2026-03-09

This listing is for informational purposes only and does not constitute an endorsement or recommendation. Always consult directly with healthcare providers about treatment options.

American Board of Internal Medicine — Medical Oncology American Board of Internal Medicine — Internal Medicine
Specialty
Medical Oncology
Hospital
University of Chicago Medicine
Location
Chicago, IL
Board Certifications
2
Publications
200+

Biography

Dr. Hedy Kindler is one of the foremost medical oncologists specializing in mesothelioma in the world. Based at the University of Chicago, she has served as principal investigator on multiple landmark mesothelioma clinical trials that have shaped treatment standards. Dr. Kindler is recognized as a key opinion leader in mesothelioma treatment and is frequently invited to present at international conferences. Her research spans both pleural and peritoneal mesothelioma, with particular expertise in immunotherapy and targeted therapy.

Education & Training

  • Medical Degree — Northwestern University Feinberg School of Medicine (Medicine)
  • Residency — University of Chicago (Internal Medicine)
  • Fellowship — University of Chicago (Hematology/Oncology)

Specialties & Procedures

Clinical Specialties

  • Medical Oncology
  • Gastrointestinal Oncology
  • Mesothelioma

As a medical oncologist, Dr. Hedy Kindler focuses on non-surgical treatment modalities including chemotherapy, immunotherapy, targeted therapy, and clinical trials.

Board Certifications

  • American Board of Internal Medicine — Medical Oncology
  • American Board of Internal Medicine — Internal Medicine

Research Focus

Clinical trials for mesothelioma, immunotherapy for peritoneal and pleural mesothelioma, and novel drug development for rare cancers.

Notable Publications

  • Randomized phase II trial of gemcitabine plus cisplatin with or without bevacizumab in patients with malignant mesothelioma. Journal of Clinical Oncology, 2012.

Treatment Center

Dr. Hedy Kindler practices at University of Chicago Medicine in Chicago, IL.

View University of Chicago Medicine Profile →

Legal Resources for Mesothelioma Patients

Patients diagnosed with mesothelioma after asbestos exposure may be eligible for compensation through asbestos trust funds and legal claims. Over $30 billion remains available in trust funds nationwide.

Frequently Asked Questions

Why is Dr. Kindler considered a leading mesothelioma oncologist?

Dr. Kindler has been principal investigator on multiple landmark mesothelioma clinical trials and is a key opinion leader in the field. She is one of the most frequently cited researchers in mesothelioma medical oncology worldwide.

Does Dr. Kindler treat peritoneal mesothelioma?

Yes. Dr. Kindler has extensive experience treating both pleural and peritoneal mesothelioma, including clinical trials specifically designed for peritoneal mesothelioma patients.

Call Now: (800) 400-1805 Free Case Review • Available 24/7